Evermay Wealth Administration LLC elevated its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 7.1% through the 2nd quarter, in accordance with its most up-to-date Type 13F submitting with the SEC. The fund owned 9,532 shares of the corporate’s inventory after buying a further 628 shares through the interval. Evermay Wealth Administration LLC’s holdings in Johnson & Johnson have been price $1,393,000 on the finish of the latest quarter.
Different massive traders additionally lately purchased and offered shares of the corporate. Autumn Glory Companions LLC boosted its stake in Johnson & Johnson by 17.4% through the second quarter. Autumn Glory Companions LLC now owns 21,645 shares of the corporate’s inventory price $3,164,000 after shopping for a further 3,204 shares through the interval. Whalen Wealth Administration Inc. bought a brand new place in Johnson & Johnson through the second quarter price $398,000. Allegheny Monetary Group LTD boosted its stake in Johnson & Johnson by 16.6% through the second quarter. Allegheny Monetary Group LTD now owns 14,832 shares of the corporate’s inventory price $2,168,000 after shopping for a further 2,112 shares through the interval. Comgest International Buyers S.A.S. boosted its stake in Johnson & Johnson by 6.8% through the second quarter. Comgest International Buyers S.A.S. now owns 1,987,954 shares of the corporate’s inventory price $290,559,000 after shopping for a further 127,133 shares through the interval. Lastly, Hemington Wealth Administration boosted its stake in Johnson & Johnson by 0.8% through the second quarter. Hemington Wealth Administration now owns 17,892 shares of the corporate’s inventory price $2,615,000 after shopping for a further 139 shares through the interval. Institutional traders personal 69.55% of the corporate’s inventory.
Analyst Upgrades and Downgrades
JNJ has been the topic of a number of current analyst reviews. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” score to a “impartial” score and dropped their value goal for the inventory from $160.00 to $150.00 in a analysis notice on Tuesday, July twenty third. TD Cowen dropped their value goal on shares of Johnson & Johnson from $195.00 to $185.00 and set a “purchase” score for the corporate in a analysis notice on Thursday, July 18th. Royal Financial institution of Canada reissued an “outperform” score and set a $175.00 goal value on shares of Johnson & Johnson in a analysis notice on Tuesday, July thirtieth. StockNews.com raised shares of Johnson & Johnson from a “purchase” score to a “strong-buy” score in a analysis notice on Friday, August sixteenth. Lastly, Daiwa America lowered shares of Johnson & Johnson from a “strong-buy” score to a “maintain” score in a analysis notice on Tuesday, July twenty third. Seven funding analysts have rated the inventory with a maintain score, six have issued a purchase score and one has issued a robust purchase score to the inventory. In response to MarketBeat.com, the corporate at the moment has a mean score of “Average Purchase” and a consensus value goal of $173.21.
Learn Our Newest Inventory Evaluation on Johnson & Johnson
Johnson & Johnson Inventory Up 0.1 %
NYSE:JNJ opened at $167.27 on Thursday. Johnson & Johnson has a 1-year low of $143.13 and a 1-year excessive of $168.85. The corporate has a 50-day transferring common of $156.82 and a 200 day transferring common of $153.70. The agency has a market cap of $402.57 billion, a PE ratio of 10.43, a price-to-earnings-growth ratio of two.73 and a beta of 0.52. The corporate has a debt-to-equity ratio of 0.44, a present ratio of 1.07 and a fast ratio of 0.85.
Johnson & Johnson (NYSE:JNJ – Get Free Report) final launched its quarterly earnings information on Wednesday, July seventeenth. The corporate reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a internet margin of 46.34% and a return on fairness of 36.60%. The corporate had income of $22.45 billion through the quarter, in comparison with analyst estimates of $22.33 billion. Throughout the identical interval within the prior yr, the agency earned $2.80 earnings per share. The agency’s income for the quarter was up 4.3% in comparison with the identical quarter final yr. As a bunch, analysis analysts anticipate that Johnson & Johnson will publish 10.02 EPS for the present fiscal yr.
Johnson & Johnson Pronounces Dividend
The corporate additionally lately introduced a quarterly dividend, which will likely be paid on Tuesday, September tenth. Shareholders of file on Tuesday, August twenty seventh will likely be issued a $1.24 dividend. The ex-dividend date of this dividend is Tuesday, August twenty seventh. This represents a $4.96 dividend on an annualized foundation and a yield of two.97%. Johnson & Johnson’s dividend payout ratio is presently 30.92%.
Insiders Place Their Bets
In different Johnson & Johnson information, VP Robert J. Decker offered 5,635 shares of the enterprise’s inventory in a transaction dated Friday, August thirtieth. The shares have been offered at a mean value of $165.06, for a complete worth of $930,113.10. Following the completion of the transaction, the vp now immediately owns 18,973 shares within the firm, valued at $3,131,683.38. The sale was disclosed in a submitting with the Securities & Change Fee, which is accessible by way of the SEC web site. 0.16% of the inventory is at the moment owned by company insiders.
Johnson & Johnson Firm Profile
Johnson & Johnson, along with its subsidiaries, researches, develops, manufactures, and sells varied merchandise within the healthcare discipline worldwide. The corporate’s Modern Medication phase gives merchandise for varied therapeutic areas, resembling immunology, together with rheumatoid arthritis, psoriatic arthritis, inflammatory bowel illness, and psoriasis; infectious illnesses comprising HIV/AIDS; neuroscience, consisting of temper problems, neurodegenerative problems, and schizophrenia; oncology, resembling prostate most cancers, hematologic malignancies, lung most cancers, and bladder most cancers; cardiovascular and metabolism, together with thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension by way of retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.
See Additionally
Need to see what different hedge funds are holding JNJ? Go to HoldingsChannel.com to get the most recent 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Obtain Information & Scores for Johnson & Johnson Each day – Enter your e-mail tackle beneath to obtain a concise every day abstract of the most recent information and analysts’ scores for Johnson & Johnson and associated corporations with MarketBeat.com’s FREE every day e-mail publication.
